CytoMed Therapeutics Issues March 4 Press Release
Ticker: GDTC · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, filing-update
TL;DR
CytoMed dropped a press release on 3/4, details TBD.
AI Summary
On March 4, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of this press release or any specific financial figures or operational updates.
Why It Matters
This filing indicates a communication event from CytoMed Therapeutics, which could contain important updates for investors, though the specifics are not detailed here.
Risk Assessment
Risk Level: low — The filing is a routine 6-K announcing a press release without providing substantive new information, thus posing minimal immediate risk.
Key Players & Entities
- CytoMed Therapeutics Limited (company) — Registrant
- March 4, 2024 (date) — Date of press release announcement
FAQ
What was the subject of the press release issued by CytoMed Therapeutics on March 4, 2024?
The filing states that CytoMed Therapeutics Limited issued a press release on March 4, 2024, but does not specify its subject matter.
Does this 6-K filing provide any financial updates for CytoMed Therapeutics?
No, this Form 6-K filing does not provide any specific financial updates or figures for CytoMed Therapeutics.
What is the principal executive office address for CytoMed Therapeutics?
The principal executive office of CytoMed Therapeutics is located at 1 Commonwealth Lane #08-22, Singapore 149544.
Has CytoMed Therapeutics changed its name recently?
The company was formerly known as CytoMed Therapeutics Pte. Ltd. and its name change date was July 16, 2021.
Is CytoMed Therapeutics required to file Form 20-F?
Yes, CytoMed Therapeutics indicates it files annual reports under cover of Form 20-F.
Filing Stats: 407 words · 2 min read · ~1 pages · Grade level 16.4 · Accepted 2024-03-04 06:15:31
Filing Documents
- form6-k.htm (6-K) — 19KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001493152-24-008640.txt ( ) — 54KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: March 4, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman